1. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017; 3: 524-548.
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-132.
3.
Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma. Cancer Cell 2005; 8: 439-441.
4.
Torounidou N, Yerolatsite M, Zarkavelis G, Amylidi AL, Karafousia V, Kampletsas E, et al. Treatment sequencing in metastatic colorectal cancer. Contemp Oncol (Pozn) 2024; 28: 283-290.
5.
Perestrelo R, Luís C. Metabolomics in breast cancer: from biomarker discovery to personalized medicine. Metabolites 2025; 15.
6.
Żok J, Bieńkowski M, Radecka B, Kuchar A, Borowiec S, Streb J, et al. Treatment outcomes of patients with BRAF(V600E)-mutated metastatic colorectal cancer: a Polish retrospective cohort study. Contemp Oncol (Pozn) 2024; 28: 297-303.
7.
Silva C, Perestrelo R, Silva P, Capelinha F, Tomás H, Câmara JS. Volatomic pattern of breast cancer and cancer-free tissues as a powerful strategy to identify potential biomarkers. Analyst 2019; 144: 4153-4161.
8.
Silva CL, Perestrelo R, Capelinha F, Tomás H, Câmara JS. An integrative approach based on GC-qMS and NMR metabolomics data as a comprehensive strategy to search potential breast cancer biomarkers. Metabolomics 2021; 17: 72.
9.
An R, Yu H, Wang Y, Lu J, Gao Y, Xie X, et al. Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer. Cancer Metab 2022; 10: 13.
10.
Li X, Wen X, Luo Z, Tian Y, Qian C, Zhang J, et al. Development of a headspace-solid phase microextraction gas chromatography- high resolution mass spectrometry method for analyzing volatile organic compounds in urine: application in breast cancer biomarker discovery. Clin Chim Acta 2023; 540: 117236.
11.
Kliuchnikova A, Gordeeva A, Abdurakhimov A, Materova T, Tarbeeva S, Sarygina E, et al. Ovarian cancer: multi-omics data integration. Int J Mol Sci 2025; 26: 5961.
12.
Costantini S, Di Gennaro E, Fanelli G, Bagnara P, Argenziano C, Maccanico C, et al. Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy. J Exp Clin Cancer Res 2025; 44: 230.
13.
Zhou K, Yang C, Li Y. Multi-omics in colorectal cancer liver metastasis: applications and research advances. Cancer Biol Med 2025; 22: 618-638.
14.
Lin X, Xu R, Mao S, Zhang Y, Dai Y, Guo Q,et al. Metabolic biomarker signature for predicting the effect of neoadjuvant chemotherapy of breast cancer. Ann Transl Med 2019; 7: 670.
15.
Desgres M, Poyraz M, Sari B, Duhoux FP, van Marcke C, Corbet C. Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective. J Exp Clin Cancer Res 2025; 44: 234.
16.
Chen S, Zhang Y, Li X, Zhang Y, Zeng Y. Driving innovations in cancer research through spatial metabolomics: a bibliometric review of trends and hotspot. Front Immunol 2025; 16: 1589943.
17.
Wang R, Zhuang J, Zhang Q, Wu W, Yu X, Zhang H, et al. Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies. Exp Hematol Oncol 2025; 14: 99.
18.
Yerolatsite M, Torounidou N, Amylidi AL, Zarkavelis G, Hadjigeorgiou L, Lampri E, et al. The role of tumor-associated macrophages and PD-1/PD-L1 networking in colorectal cancer. Contemp Oncol (Pozn) 2025; 29: 123-130.
19.
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023; 73: 233-254.
20.
Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin 2021; 71: 333-358.
21.
Farshidfar F, Weljie AM, Kopciuk KA, Hilsden R, McGregor SE, Buie WD, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer 2016; 115: 848-857.
22.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
23.
Ohshima K. The landscape of cancer metabolism as a therapeutic target. Pathol Int 2025; 75: 387-402.
24.
Kang C, Zhang J, Xue M, Li X, Ding D, Wang Y, et al. Metabolomics analyses of cancer tissue from patients with colorectal cancer. Mol Med Rep 2023; 28: 219.
25.
Cross AJ, Moore SC, Boca S, Huang WY, Xiong X, Stolzenberg- Solomon R, et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer 2014; 120: 3049-3057.
26.
Rawluszko-WEieczorek AA, Horst N, Horbacka K, Bandura AS, Świderska M, Krokowicz P, et al. Effect of DNA methylation profile on OATP3A1 and OATP4A1 transcript levels in colorectal cancer. Biomed Pharmacother 2015; 74: 233-242.
27.
Sun L, Song L, Wan Q, Wu G, Li X, Wang Y, et al. cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res 2015; 25: 429-444.
28.
Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov 2017; 7: 716-735.
29.
Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer 2019; 19: 625-637.
30.
Bin P, Wang C, Zhang H, Yan Y, Ren W. Targeting methionine metabolism in cancer: opportunities and challenges. Trends Pharmacol Sci 2024; 45: 395-405.
31.
Brosch PK, Korsa T, Taban D, Eiring P, Kreisz P, Hildebrand S, et al. Glucose and inositol transporters, SLC5A1 and SLC5A3, in glioblastoma cell migration. Cancers (Basel) 2022; 14: 5794.
32.
Chen CH, Wang BW, Hsiao YC, Wu CY, Cheng FJ, Hsia TC, et al. PKCdelta-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. Oncogene 2021; 40: 4796-4808.
33.
Gao HF, Chen LY, Cheng CS, Chen H, Meng ZQ, Chen Z. SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK/mTOR signaling. Cancer Manag Res 2019; 11: 3171-3185.
34.
Li X, Wu Z, Yuan L, Chen X, Huang H, Cheng F, et al. Hesperidin inhibits colon cancer progression by downregulating SLC5A1 to suppress EGFR phosphorylation. J Cancer 2025; 16: 876-887.
35.
Koepsell H. The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther 2017; 170: 148-165.
36.
Wang S, Zhou Y, Yu R, Ling J, Li B, Yang C, et al. Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARgamma and SREBP2. JHEP Rep 2023; 5: 100843.
